fibrinogen concentrate + Placebo

Phase 1/2Withdrawn

0 views this week 0 watching💤 Quiet

Interest: 24/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Postpartum Hemorrhage

Conditions

Postpartum Hemorrhage

Trial Timeline

Jan 1, 2021 → Dec 1, 2021

NCT ID

NCT02528708

About fibrinogen concentrate + Placebo

fibrinogen concentrate + Placebo is a phase 1/2 stage product being developed by CSL for Postpartum Hemorrhage. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT02528708. Target conditions include Postpartum Hemorrhage.

What happened to similar drugs?

3 of 10 similar drugs in Postpartum Hemorrhage were approved

Approved (3) Terminated (0) Active (7)

✅Azithromycin + Azithromycin and amoxicillin + PlaceboMerckApproved

✅Eptacog alfa (NovoSeven)Novo NordiskApproved

✅ZULRESSO®Supernus PharmaceuticalsApproved

🔄Misoprostol + OxytocinCiplaPhase 3

🔄aripiprazoleBristol Myers SquibbPhase 3

🔄SAGE-217 15/20 mg Oral Solution + Placebo + SAGE 217 30 mg CapsulesBiogenPhase 3

🔄SAGE-217 + PlaceboBiogenPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02528708	Phase 1/2	Withdrawn	Jan 1, 2021	Dec 1, 2021	Postpartum Hemorrhage

Competing Products

20 competing products in Postpartum Hemorrhage

See all competitors

Product	Company	Stage	Hype Score
Misoprostol + Oxytocin	Cipla	Phase 3	40
Quetiapine	AstraZeneca	Phase 2	27
Azithromycin + Azithromycin and amoxicillin + Placebo	Merck	Approved	43
Eptacog alfa (NovoSeven)	Novo Nordisk	Approved	50
Eptacog alfa (activated)	Novo Nordisk	Pre-clinical	26
aripiprazole	Bristol Myers Squibb	Phase 3	40
SAGE-217 15/20 mg Oral Solution + Placebo + SAGE 217 30 mg Capsules	Biogen	Phase 3	37
SAGE-217 + Placebo	Biogen	Phase 3	37
Zuranolone	Biogen	Pre-clinical	30
Zuranolone	Biogen	Pre-clinical	30
LPCN 1154A + Placebo	Lipocine	Phase 3	30
Goserelin 3.6 mg implant + Placebo	Brain Biotech	Pre-clinical	16
ZULRESSO (brexanolone) injection	Supernus Pharmaceuticals	Pre-clinical	20
Placebo + SAGE-547 90 μg/kg/h	Supernus Pharmaceuticals	Phase 3	34
ZULRESSO®	Supernus Pharmaceuticals	Approved	37
SAGE-547	Supernus Pharmaceuticals	Phase 2	29
Placebo + SAGE-547 60 μg/kg/h + SAGE-547 90 μg/kg/h	Supernus Pharmaceuticals	Phase 3	34
SAGE-547 + Placebo	Supernus Pharmaceuticals	Phase 2	29
GH001	GH Research	Phase 2	21
Brexanolone	Brain Biotech	Pre-clinical	16